| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.04 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.069 | 0.04 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.085 | 0.05 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.05 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.05 |